PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures... (re of the Company's developmentprograms ...)

HOME >> BIOLOGY >> TECHNOLOGY

PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel

Date:11/19/2008

re of the Company's development programs, unforeseen safety issues, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). There can be no assurance that Medison will be able to successfully commercialize any of the Company's product candidates in Israeli or that the Company will generate revenue under the arrangement with Medison. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at http://www.pharmathene.com.

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008

Post Your Comments:

(Date:11/20/2009)...tin American countries have an opportunity to take...archers from the University of Valencia (UV), work...died the productive fabric of the Spanish biotechn...ood and plant sectors have more clout than those i... applied to food and plants has been overlooked by...

(Date:11/20/2009)... SEATTLE, Nov. 20 Cell T...ounced today that the Ninth Circuit Court of Appea...that CTI should be allowed to pursue all of its cl... to the District Court for trial. CTI filed a com...party reimbursement consultant for CTI,s product T...

(Date:11/19/2009)...TTLE, Nov. 19 Omeros Cor...d financial results for the third quarter ended Se...mber 30, 2009, Omeros reported a net loss of $3.9 ...loss of $7.4 million, or $2.54 per share, for the ...tember 30, 2009, the Company reported a net loss o...

(Date:11/19/2009)... MALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PRNewsw...sion Resources find that the leading driver of ant...e is broad-spectrum activity against gram-positive...f organisms that can cause nosocomial pneumonia, s...primarily for agents that provide appropriate cove...

Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2 Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2 Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2 Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3 Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4 Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5 Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6 Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7 Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8 Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2 Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3

[1] Spanish biotechnology should focus on food and plant sectors to be more competitive [0] Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group [0] Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights [0] Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe

...VER, Nov. 5 /PRNewswire-FirstCall/ - OncoGenex,Pha... the Company,s third,quarter financial results wil...t the Company will host a conference call and live...nt will discuss the company,s third,quarter result...t pipeline., To access the webcast, log on to the...

...swire-FirstCall/ - Oncolytics Biotech Inc.,(TSX:ON...day announced its,financial results for the three ...Recent Pivotal Trial Decision, Oncolytics made a ...ase,II/III) randomized trial using the combination...ractory patients with head and neck cancers.,The d...

... Nov. 4 Cambrex,Corporation (NYSE: CBM ) reports...eptember 30, 2008., (Logo: http://www.newscom...es increased 3.2% (-1.7% excluding foreign currenc...d EBITDA for the quarter was up $1.7 million to $1... Debt, net of cash was $92.0 million at the end of...

OncoGenex Pharmaceuticals to Release Third Quarter Financial Results Oncolytics Biotech Inc. Announces 2008 Third Quarter Results Cambrex Reports Third Quarter 2008 Results

(Date:11/23/2009)...e in German . , Not just birds, but also a .... Researchers at Princeton University in the U.S. ... Radolfzell, Germany studied the migratory behavio...lled "Vespertilionidae" with the help of mathemati...r short as well as long distances of various kinds...

(Date:11/22/2009)...posed prenatally to tobacco smoke and during child...D, according to research done at Cincinnati Childr...tes that up to 35 percent of ADHD cases in childre... eliminating both of these environmental exposures... , "Tobacco and lead exposure each have their o...

(Date:11/22/2009)...cientists have inventoried an astonishing abundanc...that have never known sunlight - creatures that so... to 5,000 meters (~3 miles) below the ocean waves....ther vanguard technologies, animals known to thriv... a diverse collection of species ranging from crab...

[0] We're off then: The evolution of bat migration [0] Exposure to lead, tobacco smoke raises risk of ADHD [0] Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss

...at the San Francisco VA Medical Center will be tra...onur, Kazakhstan, this Saturday, Sept. 2, 2006, to...ate how human immune response is suppressed in the...-Fulford, PhD, director of the Laboratory of Cell ...Secretary of the U.S. Department of Veterans Affai...

...atest quake - to strike the Indonesian island of J... Task Force (RDRTF). Under the leadership of Dr. R...sending two scouts to join a team from Médecins Sa... Dr. Arjan van der Tol, Nephrologist, (who also pa... November 2005), and Mr. Stefaan Claus, Renal Nurs...

... the body,s first line of defense against bacteria...s with compromised immune systems, according to re...cine ?Northwest. , In the July 28 issue of the Jo...D., and Dipika Gupta, Ph.D., propose that the prot...ld boost the body,s impaired day-to-day response t...

Other Biology News:Scientist-astronaut sends T-cells into space 2 Scientist-astronaut sends T-cells into space 3 Indonesia - disaster relief aid in action 2

Scientist-astronaut sends T-cells into space Indonesia - disaster relief aid in action Role of protein in immune response may aid HIV research

GIBCO Hanks Balanced Salt Solution (HBSS) (1X); liquid from Invitrogen

BLOCK-iT Adenoviral RNAi Expression System from Invitrogen

pCC1BAC/plndigoBAC-5 Reverse Sequencing Primer from EPICENTRE Biotechnologies

...ervices ,,GenScript offers many antibody m...nd antibody fragmentation. Labeling antibodies wit...n and quantitation of the target molecule. In some...binding (Fab) portion of the antibody. For these a...

Biology Products:

GIBCO Hanks Balanced Salt Solution (HBSS) (1X); liquid from Invitrogen BLOCK-iT Adenoviral RNAi Expression System from Invitrogen pCC1BAC/plndigoBAC-5 Reverse Sequencing Primer from EPICENTRE Biotechnologies Antibody Modification Services from Genescript

PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures...(re of the Company's developmentprograms ...)